Evolus, Inc. ( (EOLS) ) has released its Q4 earnings. Here is a breakdown of the information Evolus, Inc. presented to its investors.
Evolus, Inc. is a performance beauty company focused on developing an aesthetic portfolio, primarily operating in the beauty and personal care industry with a unique customer-centric business model and innovative digital platform.
Evolus, Inc. recently announced its record-breaking financial results for the fourth quarter and full year of 2024, highlighting significant revenue growth and profitability achieved ahead of expectations. The company also reaffirmed its guidance for 2025, indicating continued strong performance.
In the fourth quarter of 2024, Evolus reported a global net revenue of $79.0 million, marking a 30% increase from the previous year. For the full year, the company achieved $266.3 million in net revenue, representing a 32% growth over 2023. Evolus also reported a positive non-GAAP operating income of $6.7 million for the fourth quarter, contributing to a full-year profitability milestone reached a year earlier than anticipated. The company attributes its success to the strong performance of its flagship product, Jeuveau, and the upcoming launch of Evolysse, which recently received FDA approval.
Looking ahead to 2025, Evolus projects net revenues between $345 million and $355 million, reflecting a 30% to 33% growth from 2024. The company anticipates that its new products, Evolysse and Estyme injectable HA gels, will contribute 8-10% of total revenue. Evolus plans to launch Evolysse in the U.S. in the second quarter, with significant investments in medical education and sampling to drive adoption.
Evolus remains focused on transforming into a multi-product beauty company, with a strategic plan to achieve at least $700 million in net revenue by 2028. The management is optimistic about expanding its product portfolio and maintaining strong growth, aiming for a non-GAAP operating income margin of at least 20% by 2028, thereby creating long-term value for shareholders.